# A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

> **NCT01638715** · PHASE4 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 115 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Remicade
- **DRUG:** Orencia
- **DRUG:** Ro-Actemra
- **DRUG:** Mabthera

## Key facts

- **NCT ID:** NCT01638715
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2018-08-01
- **Final completion:** 2018-08-01
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01638715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01638715, "A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01638715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*